Communities demand ViiV/GSK accelerate access to CAB-LA in LMICs

View full statement here

We are sharing a statement from nearly 200 community representatives and organisations who are concerned about the continued delay by ViiV/GSK to announce a Cabotegravir Long-Acting injectable (CAB-LA) access plan in LMICs.

CAB-LA offers a badly needed option for individuals at risk of HIV infection for whom daily PrEP use is not preferred or feasible. It helps overcome many barriers associated with daily pills while adding to the much-needed diversity in HIV prevention tools that the community has for years been calling for.

The statement is calling upon ViiV/GSK to immediately license CAB-LA to generic manufacturers to ensure its affordable and widespread access in LMICs. The community is asking them to urgently update their access plans using the DTG license agreement and geographic scope as the absolute minimum, while also ensuring the licensing process with generic manufacturers is open and transparent.

ViiV/GSK has set a very high standard in ensuring equity for all people to access its ARVs. This is the time to act and ramp up on that standard. The young men, women, and the entire community aspiring for an HIV free generation eagerly await their announcement that responds to the asks contained in the above statement. We urge ViiV/GSK to live up to their reputation as an innovator with public health at the heart of all their access policies.

Published: March 1, 2022
Last edited: March 10, 2022